会议报道

订阅

MedSci主页 / 所有栏目 / 会议报道

梅斯作为会议媒体参加ENDOVASCOLOGY2016—国际腔内血管学大会全新日程一览表

2016-09-28 MedSci MedSci原创

腔内血管学景在平
关注






版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938628, encodeId=6d1d19386284b, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 24 03:26:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276872, encodeId=628c12e6872ee, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 30 02:26:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137377, encodeId=e8b013e377d3, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:22 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137376, encodeId=848413e376d4, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:16 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2017-05-24 quxin068

    #ASC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1938628, encodeId=6d1d19386284b, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 24 03:26:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276872, encodeId=628c12e6872ee, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 30 02:26:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137377, encodeId=e8b013e377d3, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:22 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137376, encodeId=848413e376d4, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:16 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-30 一闲

    #梅斯#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1938628, encodeId=6d1d19386284b, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 24 03:26:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276872, encodeId=628c12e6872ee, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 30 02:26:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137377, encodeId=e8b013e377d3, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:22 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137376, encodeId=848413e376d4, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:16 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 知难而进

    继续关注！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938628, encodeId=6d1d19386284b, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed May 24 03:26:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276872, encodeId=628c12e6872ee, content=<a href='/topic/show?id=bde16242956' target=_blank style='color:#2F92EE;'>#梅斯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62429, encryptionId=bde16242956, topicName=梅斯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Sep 30 02:26:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137377, encodeId=e8b013e377d3, content=继续关注！, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:22 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=137376, encodeId=848413e376d4, content=谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Wed Sep 28 22:05:16 CST 2016, time=2016-09-28, status=1, ipAttribution=)]
    2016-09-28 知难而进

    谢谢分享！

    0

相关资讯

景在平：创新是一种习惯MedSci专访 2014国际腔内血管学大会：

edSci：景主任，感谢您接收medsci的采访，首先预祝我们大会的成功举办，我们得知您荣获首届中国医师协会腔内血管学专业委员会主任委员，在这里恭喜您，您一直致力于血管系统疾病的临床研究并取得了丰硕的成果，腔内血管学是一个比较新的概念，在我们国家发展咱很快，您能简单给我们介绍一下这个概念吗？ 景主任：专业委员会的创建，我们从启动花了25年，美国和欧洲都失败了，在中国第一次，独立于，腔内血管学

文而化之，必能长而海之--人文科普论坛

2015年10月8日至10日由长海医院血管外科主办的2015年国际腔内血管学大会于上海隆重召开。大会力求搭建国际平台，展示前沿技术，激发热点讨论，演示精彩手术。而在2015年10月10日星期六有一场科普人文的论坛。在学术氛围浓厚的国际腔内血管大会的议程中，医学作为与人类生命息息相关的一门科学，有着深厚的人文渊源和人文本性，医学发展的根本动力源于医学工作者们对患者疾苦和人类命运的人文关怀，在当今医学

梅斯作为会议媒体参加2016年国际腔内血管学大会

中国医师协会腔内血管学21个专委会在沪宣布成立

今天，由长海医院血管外科主办的2015年国际腔内血管学大会在上海隆重开幕。具有历史意义的是，在本届大会上成立了中国医师协会腔内血管学专业委员会领导下的21个专委会。在今天下午的大会上，进行了中国医师协会腔内血管学专业委员会各专委会的选举投票和成立仪式。中国医师协会腔内血管学专委会主任委员、长海医院血管外科主任景在平教授在致辞中指出：“分委会成立以后，将通过组织学术交流，邀请专家协助，进行本专业人员

2014国际腔内血管学大会--大会亮点

2014年国际腔内血管学大会在10月9日至12日在上海隆重召开。会议已经接近尾声，MedSci小编带您一起走进国际腔内血管学大会，看看这次会议的亮点吧。 一会三展​ 大会将延续以往的会议架构，融合三个展会，包括工业展、书画展及学术展。工业展上将展示最新及最尖端的腔内血管器具，为参会者提供接触、试用最新产品的平台，并让参会者和器具开发研制者面对面交流，从而提高与会者对精尖器具及潮流的认识。书

2014国际腔内血管学大会---MedSci**花絮

2014国际腔内血管学会议于10/9-10/11在上海外高桥喜来登酒店召开！跟着MedSci小编的脚步，我们一起感受下会场的热烈气氛吧！ （主会场座无虚席，旁边和后方还站了不少） （会场外人员也不少，本次会议依旧吸引了不少外宾） （讨论的好开森！左1的专家，看侧影怎么这么熟悉？-猜对送积分哟！） （中国医师协会腔内血管学专业委员会选举大会，恭喜上海长海医院景